48 Weeks After a Single Treatment: A New Era for Solid Tumor Care – CancerWorld
CancerWorld shared a post on LinkedIn:
“A cancer patient given no options left… walks into the hospital alive and thriving—48 weeks after a single treatment… Radiologic, clinical, and biochemical markers confirmed complete remission.
That’s not a plot twist from a medical drama. It’s real. And it’s the work of Dr. Jennifer S. Buell, CEO of MiNK Therapeutics.
Dr. Buell and her team have harnessed a rare type of immune cell, iNKT cells, to create an off-the-shelf therapy that can be shipped anywhere in the world.
- No patient-specific matching.
- No high-toxicity conditioning.
- No lymphodepletion.
Just immune restoration at a scale and accessibility the world has never seen before.
Why this matters:
- Treats solid tumors—not just blood cancers
- Minimal side effects, maximum immune power
- Democratizes access to advanced cell therapy
And it all started with a children’s book about Louis Pasteur, a childhood battle with meningitis, and a belief that science could—and should—save lives everywhere.
Read the full CancerWorld cover story.”
More posts featuring CancerWorld.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023